These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12639818)

  • 1. Gallium arsenide exposure impairs splenic B cell accessory function.
    Gondre-Lewis TA; Hartmann CB; Caffrey RE; McCoy KL
    Int Immunopharmacol; 2003 Mar; 3(3):403-15. PubMed ID: 12639818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gallium arsenide modulates proteolytic cathepsin activities and antigen processing by macrophages.
    Lewis TA; Hartmann CB; McCoy KL
    J Immunol; 1998 Sep; 161(5):2151-7. PubMed ID: 9725206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gallium arsenide exposure impairs processing of particulate antigen by macrophages: modification of the antigen reverses the functional defect.
    Hartmann CB; McCoy KL
    Life Sci; 2004 Jun; 75(4):485-98. PubMed ID: 15147834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gallium arsenide selectively suppresses antigen processing by splenic macrophages for CD4+ T cell activation.
    Lewis TA; Munson AE; McCoy KL
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1244-51. PubMed ID: 8819508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of splenic accessory cell function in mice exposed to gallium arsenide.
    Sikorski EE; Burns LA; McCoy KL; Stern M; Munson AE
    Toxicol Appl Pharmacol; 1991 Aug; 110(1):143-56. PubMed ID: 1714636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gallium arsenide augments antigen processing by peritoneal macrophages for CD4+ helper T cell stimulation.
    Hartmann CB; McCoy KL
    Toxicol Appl Pharmacol; 1996 Dec; 141(2):365-72. PubMed ID: 8975760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of in vitro gallium arsenide exposure on macrophages.
    Harrison MT; Hartmann CB; McCoy KL
    Toxicol Appl Pharmacol; 2003 Jan; 186(1):18-27. PubMed ID: 12583989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct exposure to gallium arsenide upregulates costimulatory activity of murine macrophages.
    Caffrey-Nolan RE; McCoy KL
    Toxicol Appl Pharmacol; 1998 Aug; 151(2):330-9. PubMed ID: 9707509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotoxicity of gallium arsenide on antigen presentation: comparative study of intratracheal and intraperitoneal exposure routes.
    Hartmann CB; Harrison MT; McCoy KL
    J Immunotoxicol; 2005 Jan; 2(1):1-9. PubMed ID: 18958654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Splenic cell targets in gallium arsenide-induced suppression of the primary antibody response.
    Sikorski EE; Burns LA; Stern ML; Luster MI; Munson AE
    Toxicol Appl Pharmacol; 1991 Aug; 110(1):129-42. PubMed ID: 1871769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gallium arsenide selectively inhibits T cell proliferation and alters expression of CD25 (IL-2R/p55).
    Burns LA; Munson AE
    J Pharmacol Exp Ther; 1993 Apr; 265(1):178-86. PubMed ID: 8097242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotoxicity of the semiconductor gallium arsenide in female B6C3F1 mice.
    Sikorski EE; McCay JA; White KL; Bradley SG; Munson AE
    Fundam Appl Toxicol; 1989 Nov; 13(4):843-58. PubMed ID: 2695379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficiency of antigen presentation after antigen targeting to surface IgD, IgM, MHC, Fc gamma RII, and B220 molecules on murine splenic B cells.
    Snider DP; Segal DM
    J Immunol; 1989 Jul; 143(1):59-65. PubMed ID: 2471743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gallium arsenide selectively up-regulates inflammatory cytokine expression at exposure site.
    Becker SM; McCoy KL
    J Pharmacol Exp Ther; 2003 Dec; 307(3):1045-53. PubMed ID: 14560044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gallium arsenide differentially affects processing of phagolysosomal targeted antigen by macrophages.
    Lewis TA; Hartmann CB; McCoy KL
    J Leukoc Biol; 1998 Mar; 63(3):321-30. PubMed ID: 9500519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA-mediated transfer of major histocompatibility class II I-Ab and I-Abm12 genes into B lymphoma cells: molecular and functional analysis of introduced antigens.
    Ben-Nun A; Choi E; McIntyre KR; Leeman SA; McKean DJ; Seidman JG; Glimcher LH
    J Immunol; 1985 Aug; 135(2):1456-64. PubMed ID: 3925010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for arsenic as the immunosuppressive component of gallium arsenide.
    Burns LA; Sikorski EE; Saady JJ; Munson AE
    Toxicol Appl Pharmacol; 1991 Aug; 110(1):157-69. PubMed ID: 1651571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of gallium arsenide-induced suppression of the antibody-forming cell response by vehicle supernatants. I. Pharmacokinetics after in vitro and in vivo exposure.
    Burns LA; Munson AE
    J Pharmacol Exp Ther; 1993 Apr; 265(1):144-9. PubMed ID: 8386233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutathione depletion reveals impairment of antigen processing and inhibition of cathepsin activity by nitric oxide in antigen-presenting cells.
    Lemaire G; Guittet O; Vesin MF; Lepoivre M; Cottet MH
    Mol Immunol; 2009 Mar; 46(6):1100-8. PubMed ID: 19095306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mutant antigen-presenting cell defective in antigen presentation expresses class II MHC molecules with an altered conformation.
    Dang LH; Lien LL; Benacerraf B; Rock KL
    J Immunol; 1993 May; 150(10):4206-17. PubMed ID: 8482833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.